tislelizumab + spartalizumab

**tislelizumab + spartalizumab** is an investigational combination of two anti-programmed death-1 (PD-1) monoclonal antibodies for the treatment of solid tumors and hematologic malignancies. Both agents function as immune checkpoint inhibitors, blocking the PD-1 pathway and releasing immune system inhibition to allow for increased anti-tumor T-cell activity. Tislelizumab, developed by BeiGene, is engineered to minimize binding to Fcγ receptors on macrophages to reduce antibody-dependent phagocytosis and to provide potent and highly specific blockade of PD-1. Spartalizumab, developed by Novartis, is a humanized IgG4κ monoclonal antibody also targeting PD-1, blocking its interactions with both PD-L1 and PD-L2, thereby potentiating antitumor immune responses. The safety and anti-tumor activity of these agents as monotherapies have been established in multiple cancer types, but there is, as of August 2025, no evidence that the direct combination of tislelizumab and spartalizumab (without other agents) has been formally studied or advanced beyond very early-phase conceptualization in clinical trials. Both drugs are being evaluated in combination regimens, but the dual-PD-1 inhibitor combination is experimental and not standard practice.